HONG KONG – Over the next year, health authorities in China plan to renew their focus on biotech development and continue funding research and development of new drugs to the tune of $3.2 billion. Read More
Advaxis Inc., of Princeton, N.J., was issued Japanese Patent No. 5479918, “Compositions and Methods for Enhancing Immunogenicity of Antigens.” The patent covers the use of ADXS-HPV for the treatment of late-stage cervical cancer. Read More
China Biologic Products Inc., of Beijing, said it received the good manufacturing practice certification from the CFDA for its plasma production facility at its Guizhou subsidiary. That will allow the firm to resume full-scale commercial production later this month for all of its approved plasma products, including the newly approved human prothrombin complex concentrate. Read More
SHANGHAI – Hua Medicine Ltd. has commenced a phase Ib trial for HMS5552, a glucokinase activator (GKA), in early stage type 2 diabetes patients in a multicenter, multidose study in China. Read More
SHANGHAI – There are more bees than flowers in the China biopharma space, with venture capital (VC) interest outstripping the number of early stage companies with novel biologics to develop. Read More
